The updated results from the LOTIS-2 clinical trial show that ZYNLONTA has durable, long-term responses in relapsed/refractory DLBCL patients. This positive data will be presented at two major conferences, which could potentially increase the visibility and credibility of the drug. As a result, this news is likely to have a positive short-term impact on ADC Therapeutics' stock price.